Fast Approval Of Pandemic Flu Vaccines With Adjuvants Could Face Regulatory Barrier
This article was originally published in The Pink Sheet Daily
Executive Summary
Current FDA regulations may pose a barrier to fast approval of pandemic influenza vaccines that include an adjuvant for novel strains, HHS' National Vaccine Program Office says.